

The background of the slide is a photograph of the Golden Gate Bridge in San Francisco, California. The bridge's red-orange towers and suspension cables are visible against a clear blue sky. The water of the bay is visible at the bottom, with a small white sailboat in the distance. The overall scene is bright and clear.


# **Obesity I: Overview and Molecular and Biochemical Mechanisms**

**Robert H. Lustig, M.D., M.S.L.  
Division of Endocrinology, Department of Pediatrics  
Institute for Health Policy Studies  
University of California, San Francisco**

**Adjunct Faculty, Touro University-California  
Adjunct Faculty, UC Hastings College of the Law**

# “Exclusive” view of obesity and metabolic dysfunction

260 million adults in U.S.



Araujo et al. Met Synd Rel Dis 17:46, 2019; Tomiyama et al. Int J Obes 40:883, 2016  
Chen et al. J Clin Endocrinol Metab 100:4082, 2015

<https://www.cdc.gov/nchs/products/databriefs/db360.htm>

# “Exclusive” view of obesity and metabolic dysfunction

260 million adults in U.S.

150 million

110 million

Obese (42.4%)

Normal weight (57.6%)

Obese and sick  
(80% of 42.4%)

86 million

Araujo et al. *Met Synd Rel Dis* 17:46, 2019; Tomiyama et al. *Int J Obes* 40:883, 2016  
Chen et al. *J Clin Endocrinol Metab* 100:4082, 2015

<https://www.cdc.gov/nchs/products/databriefs/db360.htm>

# “Exclusive” view of obesity and metabolic dysfunction

260 million adults in U.S.

150 million

110 million

Obese (42.4%)

Normal weight (57.6%)

Obese and sick  
(80% of 42.4%)

NL weight and sick  
(60% of 57.6%)

86 million

90 million


**Total: 176 million sick**

Araujo et al. Met Synd Rel Dis 17:46, 2019; Tomiyama et al. Int J Obes 40:883, 2016

Chen et al. J Clin Endocrinol Metab 100:4082, 2015





<https://www.cdc.gov/nchs/products/databriefs/db360.htm>

# Relation between visceral and subcutaneous obesity: **TOFI** (thin on the outside, fat on the inside)



# THE LITTLE WOMEN OF LOJA — GROWTH HORMONE–RECEPTOR DEFICIENCY IN AN INBRED POPULATION OF SOUTHERN ECUADOR

ARLAN L. ROSENBLOOM, M.D., JAIME GUEVARA AGUIRRE, M.D., RON G. ROSENFELD, M.D.,  
AND PAUL J. FIELDER, PH.D.





# The Little Women of Loja are obese yet insulin sensitive

**Table 1.** Anthropometric Data, Lipid Metabolism, Carbohydrate Metabolism, and Insulin Sensitivity Measures for 35 Controls and 27 GHRD Subjects

	Controls	GHRD	P
<b>Anthropometrics</b>			
Age, y	39.8 (13)	34.5 (11)	.09
SDS ht	-1.7 (1.2)	-7.4 (1.2)	<.0001
BMI, kg/m <sup>2</sup>	29.4 (4.4)	27.6 (5.6)	.16
A/G fat	1.08 (0.18)	1.07 (0.09)	.79
% Fat	41.1 (6.6)	47.7 (8.9)	.0014
L/F	1.48 (0.47)	1.18 (0.48)	.016
<b>Lipids</b>			
Total C, mg/dL	199 (43.9)	229 (47.3)	.0124
HDL, mg/dL	43.5 (13.7)	50.9 (12.8)	.034
HDL-C, mg/dL	4.87 (1.33)	4.65 (1.10)	.49
LDL, mg/dL	123.1 (37.5)	157.6 (37.4)	<.0001
Apo A, g/L	1.24 (0.23)	1.34 (0.23)	.0007
Apo B, g/L	0.95 (0.24)	1.085 (0.23)	.029
VLDL, mg/dL	31.5 (18.7)	20.2 (7.6)	.0044
TG, mg/dL	158.3 (95.3)	100.7 (37.8)	.0001
<b>Carbohydrate metabolism, adipocytokines</b>			
Fasting glucose, mg/dL	93.2 (22.4)	88.6 (10.6)	.34
Postprandial glucose, mg/dL	94.1 (35.4)	77.1 (13.4)	.027
Fasting insulin, $\mu$ U/mL	13.8 (15.5)	4.29 (0.74)	.0034
HOMA2%B	141 (103)	90 (48)	.0206
HOMA2%S	108 (87)	261 (133)	<.0001
HOMA2-IR	1.74 (1.84)	0.59 (0.51)	.0025
Leptin, ng/mL	10.36 (5.24)	7.32 (4.7)	.0212
Adiponectin, mg/L	6.92 (4.41)	9.94 (4.84)	.0128
HMW adiponectin, mg/L	4.29 (2.89)	7.59 (4.07)	.0004

Abbreviations: SDS ht, SD score for height; C, cholesterol. Data are shown as mean (SD). Conversion factors: glucose to mmol/L, multiply by 0.0555; insulin to pmol/L, multiply by 6.945; LDL and VLDL to mmol/L, multiply by 0.0259; TGs to mmol/L, multiply by 0.0113.





# The Little Women of Loja are obese yet insulin sensitive

**Table 1.** Anthropometric Data, Lipid Metabolism, Carbohydrate Metabolism, and Insulin Sensitivity Measures for 35 Controls and 27 GHRD Subjects

	Controls	GHRD	P
<b>Anthropometrics</b>			
Age, y	39.8 (13)	34.5 (11)	.09
SDS ht	-1.7 (1.2)	-7.4 (1.2)	<.0001
BMI, kg/m <sup>2</sup>	29.4 (4.4)	27.6 (5.6)	.16
A/G fat	1.08 (0.18)	1.07 (0.09)	.79
% Fat	41.1 (6.6)	47.7 (8.9)	.0014
L/F	1.48 (0.47)	1.18 (0.48)	.016
<b>Lipids</b>			
Total C, mg/dL	199 (43.9)	229 (47.3)	.0124
HDL, mg/dL	43.5 (13.7)	50.9 (12.8)	.034
HDL-C, mg/dL	4.87 (1.33)	4.65 (1.10)	.49
LDL, mg/dL	123.1 (37.5)	157.6 (37.4)	<.0001
Apo A, g/L	1.24 (0.23)	1.34 (0.23)	.0007
Apo B, g/L	0.95 (0.24)	1.085 (0.23)	.029
VLDL, mg/dL	31.5 (18.7)	20.2 (7.6)	.0044
TG, mg/dL	158.3 (95.3)	100.7 (37.8)	.0001
<b>Carbohydrate metabolism, adipocytokines</b>			
Fasting glucose, mg/dL	93.2 (22.4)	88.6 (10.6)	.34
Postprandial glucose, mg/dL	94.1 (35.4)	77.1 (13.4)	.027
Fasting insulin, $\mu$ U/mL	13.8 (15.5)	4.29 (0.74)	.0034
HOMA2%B	141 (103)	90 (48)	.0206
HOMA2%S	108 (87)	261 (133)	<.0001
HOMA2-IR	1.74 (1.84)	0.59 (0.51)	.0025
Leptin, ng/mL	10.36 (5.24)	7.32 (4.7)	.0212
Adiponectin, mg/L	6.92 (4.41)	9.94 (4.84)	.0128
HMW adiponectin, mg/L	4.29 (2.89)	7.59 (4.07)	.0004

Abbreviations: SDS ht, SD score for height; C, cholesterol. Data are shown as mean (SD). Conversion factors: glucose to mmol/L, multiply by 0.0555; insulin to pmol/L, multiply by 6.945; LDL and VLDL to mmol/L, multiply by 0.0259; TGs to mmol/L, multiply by 0.0113.





# Familial Partial Lipodystrophy, Dunningan or Type 2

Peters et al. Nature Genetics. 18:292, 1998.



- X-linked or autosomal dominant
- Absence of limb fat
  - ✓ Easily visible veins
  - ✓ Defined musculature
- Normal or excess facial fat
- Cushingoid facies (moon facies)
- Dorsocervical fat pad
- Acanthosis nigricans
- Severe metabolic syndrome

# Three fat depots


# Three fat depots

1. Subcutaneous fat

# The standard model of insulin resistance

Medscape®


[www.medscape.com](http://www.medscape.com)



# The standard model of insulin resistance

Medscape®


www.medscape.com




# The standard model of insulin resistance

Medscape®


www.medscape.com



# Relationship between BMI and insulin sensitivity (N=220)



# Insulin sensitivity/resistance is more determinant of morbidity and mortality than obesity/normal weight






# Three fat depots

1. Subcutaneous fat
2. Visceral fat


# Visceral fat is due to chronic stress




# Three fat depots

1. Subcutaneous fat
2. Visceral fat
3. Ectopic (liver, and to some extent muscle) fat

# Histology of (N)AFLD




Normal



(N)AFLD

Article | Published: 08 June 2018

# NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances

Mazen Nouredin MD, MHSc , Aarshi Vipani MD, Catherine Bresee MS, Tsuyoshi Todo MD, Irene K. Kim MD, Naim Alkhouri MD, Veronica Wendy Setiawan PhD, Tram Tran MD, Walid S. Ayoub MD, Shelly C. Lu MD, Andrew S. Klein MD, Vinay Sundaram MD & Nicholas N. Nissen MD



*The American Journal of Gastroenterology* (2018) | [Download Citation](#) ↓

# NAFLD is a worldwide problem, even in normal weight people

Study	Country	n	Mode of diagnosis	NAFLD prevalence BMI <25	NAFLD prevalence BMI >25
<a href="#">Younossi et al.2012</a>	United States	11,613	Ultrasound	9.6%	28.8%
<a href="#">Xu et al.2013</a>	China	6,905	Ultrasound	7.2%	Not studied
<a href="#">Das et al.2010</a>	India	1,911	Ultrasound/CT	5.1%	31.7%
<a href="#">Kwon et al.2012</a>	Korea	29,994	Ultrasound	12.6%	50.1%
<a href="#">Bellentani et al.2000</a>	Italy	257	Ultrasound	16.4%	75.8%
<a href="#">Sinn et al.2012</a>	Korea	5,878	Ultrasound	27% (BMI 20-25) 16% (BMI <20)	Not studied
<a href="#">Wei et al.2015</a>	Hong Kong	911	Magnetic Resonance	19.3%	60.5%


Kumar and Mohan, J Clin Trans Hepat 5:216, 2017

# Liver fat is a driver of diabetes, even in normal weight people




# Adolescent NAFLD and future risk for diabetes

## RR = 2.59






# MRI Fat Fraction Maps



Obese

Low Liver Fat = 2.6%


# MRI Fat Fraction Maps



Obese


Low Liver Fat = 2.6%

# MRI Fat Fraction Maps



Obese


Low Liver Fat = 2.6%



Obese


High Liver Fat = 24%

# MRI Fat Fraction Maps



Obese


Low Liver Fat = 2.6%




Obese

High Liver Fat = 24%

# MRI Fat Fraction Maps



Obese  
Low Liver Fat = 2.6%




Obese  
High Liver Fat = 24%




Normal Weight  
High Liver Fat = 23%

# MRI Fat Fraction Maps



Obese

Low Liver Fat = 2.6%



Obese


High Liver Fat = 24%



Normal Weight

High Liver Fat = 23%


# MRI Fat Fraction Maps



Obese

Low Liver Fat = 2.6%

Fat Healthy



Obese

High Liver Fat = 24%

Fat Sick



Normal Weight

High Liver Fat = 23%

Thin Sick


# A different model of insulin resistance



The liver is the primary fat depot




# A different model of insulin resistance



The liver is the primary fat depot

# A different model of insulin resistance



The liver is the primary fat depot

# Both adipose tissue and liver transcription factors promote fat cell differentiation


Adipose Tissue Transcription Factors	Abbreviation
Peroxisome proliferator-activated receptor gamma (heterodimer with RXR)	PPAR $\gamma$
Peroxisome proliferator-activated receptor alpha	PPAR $\alpha$
Peroxisome proliferator-activated receptor beta/delta	PPAR $\beta/\delta$
Retinoid X receptor (heterodimer with PPAR $\gamma$ )	RXR

Liver Transcription Factors	Abbreviation
Liver X receptor	LXR
Pregnane X receptor	PXR
Constitutive androstane receptor	CAR
Farnesoid X receptor	FXR
Aryl hydrocarbon receptor	AhR


# Endocrine hormone receptors promote energy deposition and fat cell growth

Hormone receptor	Abbreviation
Insulin receptor	IR
Estrogen receptors	ER ( $\alpha$ , $\beta$ )
Androgen receptor	AR
Glucocorticoid receptor	GR
Thyroid hormone receptors	TR ( $\alpha$ , $\beta$ )


# Endocrine control of metabolism



# Endocrine control of metabolism



# Insulin blocks leptin signaling – “brain starvation”



# **Fetal origins of obesity**

- 1. Small for gestational age and developmental programming**
- 2. Large for gestational age and epigenetics**
- 3. Prenatal stress and glucocorticoids**
- 4. Environmental exposures (e.g. DDE, BPA, PFAS, fructose)**